NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Nearly 6,000 patients have been treated with the drug since 2017
Company working on COVID vaccine INO 4800
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Subscribe To Our Newsletter & Stay Updated